Dejan Jakimovski, MD, PhD, Buffalo Neuroimaging Analysis Center, Buffalo, NY, delves into the ongoing debate concerning the cessation of treatment for multiple sclerosis (MS) patients. The recent DISCOMS trial highlighted the ambiguity in determining the non-inferiority between therapy discontinuation and continuation. Presently, decisions on continuing or discontinuing treatment are majorly hinged on inflammation indicators, like relapses or MRI lesions. Dr Jakimovski emphasizes the need for a more nuanced understanding, particularly concerning how discontinuation impacts long-term disability progression. Preliminary findings suggest that therapy cessation may be linked to accelerated progression. However, given the need for further evidence, Dr Jakimovski advises clinicians to be cautious before altering their current practices. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.